1
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Timothy M Caldwell, Bertrand L Chenard, Stéphane De Lombaert, Kevin J Hodgetts: Substituted quinolin-4-ylamine analogues. Neurogen Corporation, Edwards Angell Palmer & Dodge, Peter F Corless, Mark D Russett, February 10, 2009: US07488740 (6 worldwide citation)

Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion ...


2
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Timothy M Caldwell, Bertrand L Chenard, Stéphane De Lombaert, Kevin J Hodgetts: Substituted quinolin-4-ylamine analogues. Neurogen Corporation, Edward Angell Palmer & Dodge, November 19, 2009: US20090286767-A1

Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion ...


3
Harry R Howard, John E Macor, Bertrand L Chenard, Jeffrey S Sprouse, David W Schulz: Compositions containing sertraline and a 5-HT.sub.1D receptor agonist or antagonist. Pfizer, Peter C Richardson, Paul H Ginsburg, Garth Butterfield, January 28, 1997: US05597826 (39 worldwide citation)

The present invention relates to novel compositions containing the serotonin selective re-uptake inhibitor (SSRI), preferably (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenam ine, and an agonist or antagonist of the serotonin 1 (5-HT.sub.1) receptor and to the use of such c ...


4
Bertrand L Chenard, Willard M Welch, Frank S Menniti: Methods of administering AMPA receptor antagonists to treat dyskinesias associated with dopamine agonist therapy. Pfizer, Peter C Richardson, Paul H Ginsberg, Kristina L Konstas, October 24, 2000: US06136812 (29 worldwide citation)

The invention relates to a method of treating dyskinesias associated with dopamine agonist therapy in a mammal which comprises administering to said mammal a compound, as defined herein, which is an antagonist of the AMPA receptor. Dopamine agonist therapy, as referred to in the present invention, i ...


5

6
Bertrand L Chenard, Frank S Menniti: Combinations for the treatment of parkinsonism containing selective NMDA antagonists. Pfizer, Peter C Richardson, Gregg C Benson, Robert T Ronau, July 10, 2001: US06258827 (21 worldwide citation)

This invention relates to a method of treating Parkinson's Disease whereby a mammal suffering from Parkinson's Disease is treated with a combination of a forebrain selective NMDA antagonist and a compound which is capable of increasing the excitatory feedback from the ventral lateral nucle ...


7
Bertrand L Chenard: Neuroprotective indolone and related derivatives. Pfizer, Peter C Richardson, Gregg C Benson, John D Conway, March 12, 1996: US05498610 (19 worldwide citation)

The present invention is directed to a method of blocking N-methyl-D-aspartic (NMDA) acid receptor sites in a mammal in need thereof with an effective NMDA blocking (neuroprotective and antiischemic) amount of 5-(1-hydroxy-2-piperidino)-propyl-2(1H,3H)-indolone analogs and the pharmaceutically accep ...


8
Bertrand L Chenard, Frank S Menniti, Mario D Saltarelli: Pharmaceutical combinations for the treatment of stroke and traumatic brain injury. Pfizer, Peter C Richardson, Andrea F Dorigo, November 23, 2004: US06821985 (19 worldwide citation)

This invention relates to methods of treating traumatic brain injury (TBI) or hypoxic or ischemic stroke, comprising administering to a patient in need of such treatment an NR2B subtype selective N-methyl-D-aspartate (NMDA) receptor antagonist in combination with either: (a) a sodium channel antagon ...


9
Bertrand L Chenard: Method for treating spinal cord trauma with phenolic 2-piperidino-1-alkanols. Pfizer, Peter C Richardson, Gregg C Benson, Robert T Ronau, January 14, 1997: US05594007 (18 worldwide citation)

A method of blocking N-methyl-D-aspartic acid (NMDA) receptor sites in a mammal in need thereof with an effective NMDA blocking (neuroprotective and antiischemic) amount of prodrug esters of 2-piperidino-1-alkanol derivatives and prodrug esters of 2-azabicyclo-1-alkanol derivatives and analogs and p ...


10
Bertrand L Chenard, Frank S Menniti, Mario D Saltarelli: Pharmaceutical combinations for the treatment of stroke and traumatic brain injury. Pfizer, Peter C Richardson, Stephane Drouin, Jolene W Appleman, December 23, 2003: US06667317 (18 worldwide citation)

This invention relates to methods of treating traumatic brain injury (TBI) or hypoxic or ischemic stroke, comprising administering to a patient in need of such treatment an NR2B subtype selective N-methyl-D-aspartate (NMDA) receptor antagonist in combination with either: (a) a neutrophil inhibitory ...